AbbVie has reported positive Phase 3 results for etentamig in relapsed or refractory multiple myeloma, with the investigational BCMA x CD3 bispecific T-cell engager meeting both primary endpoints in the 393-patient CERVINO trial. The objective response rate reached 74% with etentamig compared with 45.7% using investigator-selected standard available therapies, while progression-free survival favored etentamig with a hazard ratio of 0.40. That translates into a 60% reduction in the risk of disease progression or death at a median follow-up of 11.4 months.
The study enrolled patients who had already been exposed to all three major multiple myeloma treatment classes: a proteasome inhibitor, an immunomodulatory medicine and an anti-CD38 antibody. Patients had received a median of three previous lines of therapy, making CERVINO a test in a population whose treatment options were already narrowing. AbbVie says the results will support discussions with global regulators, while complete data are scheduled for presentation at the International Myeloma Society meeting later in September.
Why does a 74% response rate matter in triple-class exposed multiple myeloma?
Multiple myeloma commonly responds to treatment and then returns, requiring patients to cycle through combinations of drugs with different mechanisms. Once patients have already received proteasome inhibitors, immunomodulatory agents and anti-CD38 antibodies, finding another therapy capable of producing a high response rate becomes increasingly difficult. CERVINO directly compared etentamig with therapies physicians would ordinarily select for this heavily pretreated population rather than relying on a single-arm response benchmark.
Etentamig achieved an objective response in nearly three-quarters of treated patients, compared with fewer than half under standard available therapy. The progression-free survival result strengthens that finding because tumor shrinkage has greater clinical significance when disease control also lasts longer. AbbVie reported that the PFS advantage appeared across all prespecified subgroups evaluated.
What does the early overall survival result show?
At 12 months, overall survival was 87.9% with etentamig compared with 72% for the standard-therapy group. The estimated hazard ratio was 0.48, but AbbVie explicitly said the prespecified statistical efficacy boundary for overall survival had not been crossed at the current data cutoff.
That means the survival trend is encouraging but should not yet be described as a statistically confirmed overall survival victory. Additional deaths and longer follow-up are needed before the analysis matures sufficiently to establish whether the apparent advantage remains robust. The distinction is especially important because strong preliminary survival percentages can easily be overstated when the statistical plan has not yet reached its required threshold.
Could etentamig’s dosing schedule differentiate it from other BCMA bispecific antibodies?
AbbVie is emphasizing convenience almost as much as efficacy. Etentamig was administered monthly from treatment initiation after a single step-up dose, whereas some bispecific regimens require more complicated early dosing schedules and closer observation because of cytokine release syndrome. A simpler schedule could potentially make treatment easier to deliver in outpatient or community settings rather than concentrating care primarily at specialist academic centers.
Among patients receiving the single step-up dose, cytokine release syndrome occurred in 28.3% and was predominantly grade 1, with no grade 3 or higher CRS reported. One patient experienced grade 1 immune effector cell-associated neurotoxicity syndrome, and no grade 2 or higher ICANS occurred. These findings may support the community-treatment argument, although regulatory review and real-world experience would be needed before the operational advantages are fully established.
What safety trade-offs appeared in the Phase 3 study?
Grade 3 or 4 infections occurred in 27.7% of patients receiving etentamig compared with 19.2% receiving standard available therapies. Fatal infections occurred in 1.5% and 3.1% of the respective groups, while treatment discontinuation because of adverse events was 3.6% with etentamig versus 9.6% in the comparator group.
Serious infection risk is already an important consideration for T-cell engaging therapies because they manipulate immune activity in patients whose disease and previous treatments may already have compromised immune function. AbbVie will therefore need to establish whether etentamig’s convenient dosing and manageable CRS profile offset the infection burden sufficiently to support broad use.
What happens next for etentamig?
AbbVie intends to discuss CERVINO with regulatory authorities after presenting the complete Phase 3 dataset. The pivotal meeting presentation should provide additional details on response depth, duration of response, progression-free survival curves, subgroup outcomes and longer safety follow-up.
Etentamig’s commercial potential will ultimately depend on more than beating a heterogeneous standard-therapy control. Multiple myeloma already has CAR-T therapies and other BCMA-directed bispecifics, so the decisive question is whether monthly dosing, strong response rates and a manageable early toxicity profile are enough to make etentamig practical across a wider range of treatment centers.
